Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.



Oxford (UK), 15 July 2013 – Syntaxin, the life sciences company with expertise in the field of
botulinum toxins announced today that it has been acquired by Ipsen, with which it has two major
strategic alliances. Under the terms of the agreement, Ipsen will pay €28 million upfront, as well as
further contingent payments that could reach €130 million or more depending on the achievement
of development and commercial milestones. Furthermore, Syntaxin’s shareholders will receive the
greater part of additional downstream payments related to the company’s most advanced asset,
currently in Phase II clinical trials. Prior to the transaction, Ipsen owned c.10% of Syntaxin’s capital
on a fully diluted basis.

Syntaxin’s research laboratories in Abingdon will remain as a centre of excellence for botulinum
toxin engineering within the enlarged group, allowing Ipsen to leverage its own extensive expertise.
The Abingdon site combines with Ipsen’s R&D at Wrexham (UK) and Les Ulis (France). Syntaxin has a
wealth of experience in botulinum toxin biology, supported by an extensive patent portfolio – with
75 granted patents and over 130 patents pending.

Syntaxin and Ipsen started collaborating in 2010 and a year later they signed a global strategic
partnership to explore the discovery and development of new compounds in the field of
recombinant botulinum toxins. Syntaxin’s team has used its extensive expertise in the discovery of
new therapeutic candidates while Ipsen applied its skills to pharmacological, preclinical and clinical
assessment of the compounds.

Commenting on today’s announcement, Dr Melanie Lee, Chief Executive Officer of Syntaxin, said:
“Our established and productive collaboration with Ipsen can now be fully exploited to bring
new medicines to the market in a number of therapeutic areas.”

Dr Russell Greig, Chairman of Syntaxin, said: “This is an excellent deal for all parties. It has been a
great pleasure working with the Syntaxin Executive team led by Dr Melanie Lee as CEO. Melanie will
leave Syntaxin as will other members of her executive team including Dr Nigel Clark, CBO, Dr Phil
Boyd, CFO and Dr Jon Court, CDO, who collectively have transformed Syntaxin over the last three
years into a centre of excellence for botulinum toxin R&D”.

Syntaxin has a strong R&D portfolio which exploits the diversity of botulinum toxins, including
recombinant botulinum toxins with improved designs and properties. The Company’s technology has
been validated by the Phase II clinical trials of Syntaxin’s lead candidate. Dr Keith Foster and Dr John
Chaddock, the co-founders of Syntaxin, will join Ipsen to help the Group build a highly differentiated
and innovative toxin platform. Syntaxin’s recombinant toxin expertise and Ipsen’s know-how will be
a powerful combination to release the full potential of the Targeted Secretion Inhibitors platform
across Ipsen’s therapeutic areas of neurology, endocrinology and uro-oncology.

Syntaxin has been supported on this transaction by Rothschild and Allen & Overy LLP and Ipsen by
Lazard Ltd., Freshfields Bruckhaus Deringer LLP, and Bristows LLP(for IP matters).


For further information please contact:

Julia Phillips
Managing Director
Strategic Communications
F T I Consulting
+44 (0)20 7269 7187 direct
+44 (0)7770 827 263 mobile

Didier Véron
Vice President, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58

Pierre Kemula
Vice President, Corporate Finance, Treasury and Financial Markets
Tel.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63

About Syntaxin
Syntaxin is a UK-based private life sciences company pioneering the discovery and development of a
new class of compounds to treat diseases in a range of therapeutic areas, through its expertise in the
field of botulinum toxin biology. The Company has developed a differentiated expertise in the design,
recombinant expression and purification of botulinum toxins and Targeted Secretion Inhibitors (TSIs).
Beyond its focus on improving and expanding the use of current therapies, Syntaxin aims at
discovering new treatments through the modification and retargeting of botulinum toxins.
Syntaxin has established a wealth of experience in botulinum biology supported by an extensive
patent portfolio, with 75 granted patents and over 130 patents pending covering the platform and
products. The company owns dominant patents and know-how in the design, manufacture and use of
novel cellular TSIs that are based on engineered botulinum toxins.
Syntaxin’s Board, chaired by Dr Russell Greig, together with the Executive Management Team led by
CEO Dr Melanie Lee, provides a wealth of pharmaceutical industry experience and is backed by a
strong investor base including: Abingworth, SR One, LSP, JJDC, Lundbeckfond Ventures, Seventure,
Quest, Sutepra SAS. For more information on Syntaxin, visit

Publisher Contact Information:

F T I Consulting
+44 (0)20 7269 7187

Company profile of Syntaxin Ltd (acquired by Ipsen)
Past press releases of Syntaxin Ltd (acquired by Ipsen).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 15€6.0MArtificial Intelligence
Nov 15€3.5MSoftware development
Nov 15N/AInternet services
Nov 15€2.4MMaterials
Nov 14N/AE-Commerce
Nov 14€3.1MMedical devices
Nov 14€4.5MOther Software

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.